This is the evidence describing a product, how it is made and how its quality is controlled. It addresses product questions alongside the separate evidence about clinical outcomes.
FDA guidance for human gene-therapy investigational applications describes information intended to assure product safety, identity, quality, purity and strength, including potency. The potency-assurance guidance further connects manufacturing design, controls and testing. These sources have defined product and regulatory scopes. A manufacturing dossier, a laboratory release result and evidence that an intervention improves clinical outcomes are related but distinct parts of product development. ICH Q6B defines a specification as a list of tests, references to analytical procedures and appropriate acceptance criteria. FDA's May 2026 guidance on CMC flexibilities for cellular and gene therapy biologics licence applications is issued for immediate implementation and says its flexible approaches are not an exhaustive list, so flexibility depends on product and stage and is not an exemption.
Shares Double-stranded RNA impurities, mRNA and lipid nanoparticle manufacturing, Immune measurements and product evidence.
Shares In vitro transcription for RNA products, mRNA and lipid nanoparticle manufacturing, Immune measurements and product evidence.
Shares In vitro transcription for RNA products, Immune measurements and product evidence.
Shares In vitro transcription for RNA products, mRNA and lipid nanoparticle manufacturing.
Shares Cell-therapy release and potency testing, mRNA and lipid nanoparticle manufacturing.
Shares Cell-therapy release and potency testing, mRNA and lipid nanoparticle manufacturing.
Shares Vein-to-vein time and manufacturing slots, Cell-therapy release and potency testing.
Shares Cell-therapy release and potency testing, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/